Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × selinexor × Clear all

NCT06517511 2026-02-12

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03992339 2025-02-07

SEARCH

Phase 2 Completed

60 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse